Home 2016-10-24T12:33:21+00:00
ITG productsSlide thumbnail
Extended partnership between Radiomedix INC and ITM´s subsidiary ITG for exclusive distribution of n.c.a Lutetium-177 in North America
Slide thumbnail
RadioMedix Inc. and AREVA Med Announce Completion of the Exploratory Clinical Trial of 203Pb-AR-RMX in patients expressing somatostatin receptor positive neuroendocrine tumors
Slide thumbnail
RadioMedix, Inc., received an exclusive distributions rights for SEDECAL Preclinical PET-CT and PET-MR systems in North America.
The Phase II Clinical Trial of 177 Lu PSMA-617 Targeted Radioligand Therapy in Metastatic Castration Resistant Prostate Cancer Receives FDA Clearance
Slide thumbnail
RadioMedix and AREVA Med - SBIR NCI Contract awarded to develop targeted alpha-emitter therapy of neuroendocrine tumors with lead-212.
RadioMedix Inc. successfully completed the Phase I/ II clinical studies for AminoMedix ™ used for radiation kidney protection during Peptide-Receptor Radionuclide Therapy (PRRT)
Slide thumbnail
RadioMedix Successful Installations of SmartMedixTM  and AIO fully automated synthesizer modules in USA.
Slide thumbnail
NIH NCI SBIR Contract Award for targeted alpha-TAT of metastatic melanoma. The third collaborative grant for RadioMedix and Viewpoint.
RadioMedix and Viewpoint MT secure a second SBIR NCI grant for image guided therapy for metastatic melanoma
AREVA Med and RadioMedix partner to develop new treatment against Neuroendocrine Tumors
Slide thumbnail
Radiomedix Receives Phase I SBIR Funding from the NCI for Metastatic Melanoma Theranostics
RadioMedix Inc. launches SmartMedix™ synthesizers powered by Trasis in USA
RadioMedix featured on the cover of ACS Carbohydrate Newsletter
RadioMedix, Inc. Receives FDA Orphan Drug Designation for the 68Ga-DOTATATE (GalioMedix TM) for the management of the neuroendocrine tumors
RadioMedix Scientists Presented on the 2013 SNMMI Annual Meeting in Vancouver, Canada

Innovating Theranostics

RadioMedix, Inc. is a biotechnology company, based in Houston, Texas, focused on innovative targeted radiopharmaceuticals for diagnosis, monitoring and therapy of cancer. The company is commercializing generator-produced radiopharmaceuticals based on Gallium-68 chemistry. RadioMedix is in late-stage development of a new radiolabeled analog targeting metabolic pathway, GlucoMedix, which is based on its patented DO2A-chelation technology.

RadioMedix is introducing the SmartMedix™ automated laboratory system for synthesis of PET tracers for the research and clinical markets. RadioMedix has also established two service facilities for academic and industrial partners: cGMP Manufacturing Suite for clinical probe development and Molecular Imaging Facility for evaluation of agents in animal models.

Recent News


Extended partnership between Radiomedix INC and ITM´s subsidiary ITG for exclusive distribution of n.c.a Lutetium-177 in North America

October 10th, 2017|Comments Off on Extended partnership between Radiomedix INC and ITM´s subsidiary ITG for exclusive distribution of n.c.a Lutetium-177 in North America

RadioMedix Inc. and AREVA Med Announce Completion of the Exploratory Clinical Trial of 203Pb-AR-RMX in patients expressing somatostatin receptor positive neuroendocrine tumors

June 21st, 2017|Comments Off on RadioMedix Inc. and AREVA Med Announce Completion of the Exploratory Clinical Trial of 203Pb-AR-RMX in patients expressing somatostatin receptor positive neuroendocrine tumors

RadioMedix, Inc., received an exclusive distributions rights for SEDECAL Preclinical PET-CT and PET-MR systems in North America.

June 19th, 2017|Comments Off on RadioMedix, Inc., received an exclusive distributions rights for SEDECAL Preclinical PET-CT and PET-MR systems in North America.

The Phase II Clinical Trial of 177 Lu PSMA-617 Targeted Radioligand Therapy in Metastatic Castration Resistant Prostate Cancer Receives FDA Clearance

February 6th, 2017|Comments Off on The Phase II Clinical Trial of 177 Lu PSMA-617 Targeted Radioligand Therapy in Metastatic Castration Resistant Prostate Cancer Receives FDA Clearance

RadioMedix and AREVA Med – SBIR NCI Contract awarded to develop targeted alpha-emitter therapy of neuroendocrine tumors with lead-212.

October 31st, 2016|Comments Off on RadioMedix and AREVA Med – SBIR NCI Contract awarded to develop targeted alpha-emitter therapy of neuroendocrine tumors with lead-212.

RadioMedix Inc. successfully completed the Phase I/ II clinical studies for AminoMedix ™ used for radiation kidney protection during Peptide-Receptor Radionuclide Therapy (PRRT)

October 18th, 2016|Comments Off on RadioMedix Inc. successfully completed the Phase I/ II clinical studies for AminoMedix ™ used for radiation kidney protection during Peptide-Receptor Radionuclide Therapy (PRRT)